Tempus AI, Inc. (NASDAQ:TEM) CAO Sells $484,720.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan M. Bartolucci sold 6,059 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $80.00, for a total transaction of $484,720.00. Following the completion of the sale, the chief accounting officer now owns 47,000 shares of the company's stock, valued at approximately $3,760,000. This represents a 11.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Tempus AI Stock Down 8.4 %

Shares of Tempus AI stock traded down $7.49 during midday trading on Tuesday, hitting $81.95. 22,121,292 shares of the company traded hands, compared to its average volume of 14,109,631. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm's fifty day moving average price is $47.46 and its 200-day moving average price is $50.72. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ARK Investment Management LLC boosted its position in Tempus AI by 132.1% during the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company's stock worth $186,343,000 after buying an additional 3,141,487 shares during the period. NEA Management Company LLC boosted its position in Tempus AI by 17.8% during the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company's stock worth $304,846,000 after buying an additional 813,169 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 166.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. boosted its position in Tempus AI by 166.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after buying an additional 2,021,394 shares during the period. Finally, Franklin Resources Inc. boosted its position in Tempus AI by 240.5% during the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company's stock worth $93,251,000 after buying an additional 1,950,862 shares during the period. 24.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TEM. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and raised their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Bank of America raised their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research report on Friday, December 13th. Guggenheim assumed coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a "buy" rating and a $74.00 price target on the stock. Finally, TD Cowen reaffirmed a "buy" rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.